Nerissa T Viola-Villegas
Overview
Explore the profile of Nerissa T Viola-Villegas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKnight B, Viola-Villegas N
Breast Cancer Res
. 2018 Oct;
20(1):130.
PMID: 30359299
Background: De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-receptor...
2.
Gibson H, McKnight B, Malysa A, Dyson G, Wiesend W, McCarthy C, et al.
Cancer Res
. 2018 Aug;
78(19):5706-5717.
PMID: 30115693
IFNγ is an attractive target for imaging active antitumor immunity due to its function in the T-cell signaling axis. Here, we test an IFNγ immuno-PET (immunoPET) probe for its capacity...
3.
McKnight B, Kuda-Wedagedara A, Sevak K, Abdel-Atti D, Wiesend W, Ku A, et al.
Sci Rep
. 2018 Jun;
8(1):9043.
PMID: 29899472
Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular signatures amplified within the malignancy. The discovered crosstalk between EGFR and HER3...
4.
McKnight B, Viola-Villegas N
J Labelled Comp Radiopharm
. 2018 Jan;
61(9):727-738.
PMID: 29341222
Therapeutic monoclonal antibodies have been used in cancer treatment for 30 years, with around 24 mAb and mAb:drug conjugates approved by the FDA to date. Despite their specificity, efficacy has...
5.
Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, et al.
Sci Transl Med
. 2015 Apr;
7(283):283ra51.
PMID: 25877889
Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase α (PI3Kα) inhibitors are in clinical development. The activity of...